First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Juan Liu et al.|New England Journal of Medicine|2018Cited by 3.5k
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Alfredo Addeo, Nir Peled et al.|Journal of Thoracic Oncology|2022Cited by 97
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024Cited by 66
OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 TrialMyung‐Ju Ahn, D. Kim, D. Ross Camidge et al.|Journal of Thoracic Oncology|2017Cited by 20
P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA TrialD. Ross Camidge, D. Kim, Marcello Tiseo et al.|Journal of Thoracic Oncology|2017Cited by 3